Navigation Links
Positive results from Phase 1/2 stem cell trial reported
Date:11/6/2012

San Carlos, CA; November 6, 2012 BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter and Morph Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection. According to the results, both the allogeneic and autologous MSCs were safe and well-tolerated at all doses and demonstrated similarly positive effects on cardiac structure and function, patient functional capacity and quality of life. Results from the POSEIDON (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis) study were reported in a late breaker presentation titled, "Randomized Comparison of Allogeneic vs Autologous Mesenchymal Stem Cells in Patients with Ischemic Cardiomyopathy," at the American Heart Association's 2012 Scientific Sessions and have been published in an article in the November 6 edition of the Journal of the American Medical Association. The POSEIDON study was cosponsored by the NIH Specialized Center for Cell Therapy, the University of Miami, and BioCardia.

Joshua Hare, M.D., Director of the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine, and the POSEIDON study lead principal investigator, stated, "The combination of Allogenic MSCs with the BioCardia Helix catheter has enormous potential as a combination product for treating heart failure. The strong safety results and ease of the catheter delivery procedure in skilled hands, coupled with the potential for the use of allogeneic stem cells, suggest that this procedure may one day be as easy to perform as coronary angioplasty."

Peter Altman, Ph.D., President and CEO of BioCardia, commented, "The Helical Infusion System is intended to be the safest and easiest to use catheter for multiple clinical applications in cell- and gene-based therapy. We believe its performance and our track record of experience are second to none, and we are very optimistic about the delivery mesenchymal stem cells for the treatment of ischemic heart failure. Trial results such as POSEIDON require the talent and hard work of a dedicated team of experts, and we have been privileged to work with the clinical teams at the University of Miami and Johns Hopkins University."

Interventional cardiologist co-authors who performed the procedures in the study included Alan W. Heldman, M.D., and Juan Pablo Zambrano, M.D., at the University of Miami Miller School of Medicine, and Jeffrey A Brinker, M.D., and Peter VanDoren Johnston, M.D., at the Johns Hopkins University School of Medicine.

The Phase 1/2 POSEIDON study enrolled 31 patients with chronic ischemic left ventricular (LV) dysfunction due to ischemic cardiomyopathy (ICM). Patients were randomized to receive one of three different dose levels (20, 100, or 200 million cells) of either allogeneic MSCs or autologous MSCs. The stem cells were delivered to 10 LV sites in the myocardium by BioCardia's transendocardial stem cell injection (TESI) during retrograde left heart catheterization using BioCardia's Helical Infusion Catheter. The two catheter system fixates to the heart wall via a corkscrew needle, allowing for stable and controlled delivery of biologic therapies to the heart.

Following BioCardia's TESI, patients were hospitalized for a minimum of four days and were seen two weeks post-catheterization. Thereafter, safety and efficacy assessments using cardiac imaging studies, exercise peak VO2, a 6-minute walk test, New York Heart Association (NYHA) Class and the Minnesota Living with Heart Failure (MLHF) questionnaire were performed on a monthly basis for six months and then again at 12 months. After 13 months, all patients received follow-up CT scans of the heart, chest, abdomen and pelvis.

The primary objective of the study was to demonstrate the safety of allogeneic MSCs administered by BioCardia's TESI, determined by the incidence of any treatment-emergent serious adverse events (TE-SAEs) one month after stem cell injection. Data showed that within 30 days, one patient in each cohort was hospitalized for heart failure, a TE-SAE rate of 6.7%, substantially less than the pre-specified stopping rate of 25%. The secondary objectives were to compare the long-term safety of allogeneic MSCs to autologous MSCs and to demonstrate the efficacy of allogeneic MSCs and autologous MSCs administered by TESI in these patients. The one-year incidence of serious adverse events was not different between cell types, except for fewer ventricular arrhythmias in allogeneic recipients. Relative to baseline, allogeneic and autologous MSC therapy similarly improved the 6-minute walk and the MLHF questionnaire score, but not the exercise VO2 max. Finally, MSCs reduced infarct size (33.2%; P<0.0001), left ventricular (LV) volumes and sphericity index similarly in allogeneic and autologous groups. Importantly, allogeneic MSCs did not stimulate significant donor-specific alloimmune reactions.

A parallel Phase 1/2 study the Transendocardial Autologous Cells in Heart Failure Trial (TAC-HFT) also enabled by the BioCardia Helical Infusion System. The trial, co-sponsored by the University of Miami, is comparing autologous (bone marrow or mesenchymal) cell delivery to placebo in up to 68 cardiomyopathy patients randomized under a protocol similar to that of the POSEIDON trial. Early results in a first cohort of patients (N=8) were reported in 2011 to show that the autologous cells effected remodeling of LV shape and restoration of normal LV proportions.


'/>"/>

Contact: Miranda Peto
mpeto@biocardia.com
650-226-0129
BioCardia, Inc.
Source:Eurekalert

Related medicine news :

1. PARP inhibitors may have clinical utility in HER2-positive breast cancers
2. Religions play positive role in African AIDS crisis
3. Physicians empathy directly associated with positive clinical outcomes, confirms large study
4. Crizotinib reduces tumor size in patients with ALK positive lung cancer
5. Weight-loss surgery results in positive changes in social life, medical conditions
6. Why do older adults display more positive emotion? It might have to do with what they’re looking at
7. Study examines characteristics, risk factors among HIV-positive persons born outside the US
8. HPV testing in HIV-positive women may help reduce frequent cervical cancer screening
9. Higher levels of public reimbursement positively influence national birth rates and reduce unmet needs in subfertile populations
10. Surgeons Seek Repeal of Transplant Ban Between HIV-Positive People
11. NIH study finds HIV-positive young men at risk of low bone mass
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
Breaking Medicine Technology: